Skip to main content

Table 2 Clinical, biomarker, and demographic associations among the ADEPT moderate-severe asthma subjects in baseline clinical cluster groups

From: Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study

Variablea

Phenotype A2 (n = 37)

Phenotype A3 (n = 36)

Phenotype A4 (n = 31)

P-value

Mean [Geo.Mean] ± SD

 FEV1, pre-bd, % predicted

74.6 ± 8.2

73.8 ± 9.8

65.5 ± 11.5

3.0 x10 −4

 FVC, pre-bd, % predicted

97.4 ± 9.8

87.4 ± 10.2

88.6 ± 12.2

2.0 x10 −4

 FEV1/FVC, pre-bd

0.64 ± 0.08

0.70 ± 0.07

0.62 ± 0.10

9.0 x10 −4

 bd reversibility, % change FEV1

17.3 ± 6.6

16.5 ± 10.5

32.0 ± 21.5

1.1 x10 −5

 ACQ-7

1.1 ± 0.4

1.3 ± 0.6

2.6 ± 0.9

<10 −6

 AQLQ

6.0 ± 0.6

5.8 ± 0.9

4.1 ± 1.2

<10 −6

 FENO, ppb [Geo.Mean]

42.0 + 35.9/-20.9

15.6 + 8.8/-7.9

37.1 + 47.9/-17.8

<10 −6

 Blood eosinophils, ×1000/ul [Geo.Mean]

0.317 + 0.244/-0.134

0.124 + 0.094/-0.037

0.235 + 0.285/-0.151

<10 −6

 PC20, mg/ml [Geo.Mean]

0.5 + 1.8/-0.5

2.2 + 8.8/-2.2

0.4 + 1.4/-0.4

1.0 x10 −4

 Blood neutrophils, ×1000/ul [Geo.Mean]

3.80 + 1.64/-3.80

3.95 + 1.78/-3.95

3.67 + 1.33/-3.67

0.6916

 Blood WBC, ×1000/ul [Geo.Mean]

6.34 + 2.10/-0.35

6.35 + 2.28/-0.29

6.44 + 1.39/-0.44

0.9687

 Sputum neutrophils, % of WBCb

43.1 ± 26.6

61.6 ± 25.1

56.2 ± 22.1

0.0239

 Sputum eosinophils, % of WBC [Geo.Mean]b

7.8 + 20.7/-0.6

0.7 + 2.7/0.0

3.1 + 8.5/-0.2

<10 −6

 Age, years

43.0 ± 12.3

45.6 ± 10.7

47.9 ± 12.3

0.2340

 Age of onset, years

20.9 ± 14.2

23.4 ± 15.5

26.1 ± 18.3

0.4040

 Body Mass Index (kg/m2)

25.7 ± 3.6

27.3 ± 3.7

26.8 ± 4.2

0.2308

Percent of clinical cluster group

 Mild, no ICS (%)

na

na

na

 

 Moderate, low-medium ICS (%)

62%

58%

29%

0.0135

 Severe, high ICS (%)

38%

42%

71%

 

 Male (%)

49%

44%

48%

0.9240

 Atopic, Phadiatop positive (%)

92%

72%

71%

0.0530

 Sputum Pauci (Eos < %3, PMN < 60%) (%)b

10%

38%

22%

 

 Sputum Neutr. (Eos < 3, PMN > =60%) (%)b

14%

46%

17%

0.0003

 Sputum Mix (Eos > =3%, PMN > =60%) (%)b

14%

8%

30%

 

 Sputum Eos. (Eos > =3%, PMN < 60%) (%)b

62%

8%

30%

 

 FENO ≥ 35 ppb (%)

59%

3%

43%

1.8 x10 −6

 Blood eosinophils ≥ 300/ul (%)

54%

6%

32%

4.1 x10 −5

 FENO ≥ 35 ppb OR Blood eos. ≥ 300/ul (%)

81%

8%

55%

<10 −6

 Biopsy CCL26-high (%)c

33%

11%

29%

0.2179

  1. aSummary statistics (mean, or geometric mean where indicated, and standard deviation; or percent of clinical cluster group) and p-values from F-test (for mean/geometric mean statistics) or chisquare statistics for associations among the ADEPT clinical cluster groups, restricted to moderate-severe asthma subjects and excluding Group 1, are presented. The 9 clinical and clinical biomarker variables used in the clustering are presented first, followed by additional clinical, biomarker and demographic variable groupings
  2. bFor sputum differentials, n = 29, 24, and 23 for Groups 2, 3, and 4, respectively
  3. cFor endobronchial biopsy gene expression variables (from Affymetrix HG-U133 + PM array signal intensities), n = 21, 20, and 14 for Groups 2, 3, and 4, respectively
  4. Significant p values are captured in bold
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us